The Rise of Psychedelic Retreats: A Booming Industry With Minimal Safety Guardrails
Surging public interest in the purported therapeutic benefits of psychedelic substances has spawned an entirely new commercial sector: psychedelic retreats. These multiday experiences, where participants pay for drug-assisted sessions promising psychological healing and personal growth, have proliferated globally with hundreds of operations now available worldwide.
A Regulatory Grey Area With Significant Risks
Despite many retreats implementing safety procedures, researchers warn these operations carry "potential for physical, psychological, and interpersonal harms." A recent study published in JAMA Network Open surveyed dozens of retreats and found no industrywide standards or regulations governing how participants are screened, prepared, or monitored during and after their experiences.
"If there is no regulation, what does that mean about the quality of care you're going to have?" questioned Joshua White, founder of the Fireside Project, which operates a hotline for people experiencing distress during psychedelic trips. "I certainly fear that there could be a race to the bottom where there is no liability or accountability."
The Legal Landscape and Safety Concerns
Virtually all psychedelic drugs offered at these retreats—including magic mushrooms, ayahuasca, MDMA, and LSD—remain illegal under U.S. federal law. While some retreats claim protection under rare religious exemptions, only a handful of organizations like the Native American Church have formally obtained such legal status. Many retreats operate in countries like Peru and Brazil where psychedelics face fewer restrictions, particularly ayahuasca which has centuries of traditional use in Indigenous cultures.
With essentially no oversight, potential attendees must conduct their own research when evaluating different retreat options. "It's really important that somebody interested in a psychedelic retreat do their research, talk to the organizers or facilitators to get more information about what is being offered and how," advised Dr. Amy McGuire, a biomedical ethicist at Baylor College of Medicine and co-author of the JAMA Network Open study.
Varying Safety Standards and Medical Practices
The study documented wide variations in safety procedures and staffing credentials across different retreat operations. While many retreats employ health professionals on site, their roles and responsibilities often remain vague. In concerning cases, some medical staff take psychedelics alongside participants, potentially impairing their ability to respond effectively during emergencies.
Critical questions for prospective attendees include whether retreat staff possess proper training and equipment to handle medical emergencies, if hospitals are nearby with available transportation, and whether staff dedicate sufficient time helping participants prepare for and process their experiences. Websites compiling user reviews, such as Retreat.guru, offer one source for gathering this essential information.
Inadequate Medical Screening and Medication Discontinuation
One of the most crucial safety steps—screening out individuals with serious medical conditions who shouldn't take psychedelics—relies heavily on participant honesty. More than half of surveyed retreats exclude people with mental illnesses like schizophrenia, yet all operations depend on potential customers truthfully disclosing their medical history.
"When you're really desperate and hoping to access something that you think could help you, there's an incentive not to be truthful," noted Dr. McGuire, highlighting the risks of this approach.
Another potentially dangerous practice involves medication discontinuation. Nearly 90% of surveyed retreats require or recommend attendees stop taking certain medications, including antidepressants, before psychedelic experiences. These "washout periods" range from one day to six weeks, despite medical experts warning that safely tapering off antidepressants like Prozac typically requires six to twelve weeks under professional supervision.
"The patient needs to realize that by going off their medicine they're at greater risk of recurrence or exacerbation of their symptoms," cautioned Dr. Jeffrey Lieberman, a Columbia University psychiatrist. "They should be monitored regularly to make sure nothing bad happens."
Industry Evolution and Regulatory Developments
Industry veterans note significant improvements in safety compared to previous decades when psychedelic experiences typically occurred underground with minimal precautions. "The sheer visibility of psychedelics has led to more demand for these retreats," observed Brad Burge, who has worked with psychedelic nonprofits, drugmakers, and retreat operators for nearly twenty years. "That growing market has allowed retreats to expand their services, hire more medical and coaching staff and take safety more seriously than we've ever seen in the past."
Currently, no psychedelics have received federal approval in the United States, though this may change following recent executive action. President Donald Trump recently signed an order directing the Food and Drug Administration to accelerate reviews of psychedelics showing potential for conditions like post-traumatic stress disorder, while also instructing law enforcement agencies to quickly lower restrictions on any FDA-approved psychedelic.
The only drug to reach the FDA thus far, MDMA, was rejected as a PTSD treatment in 2024 due to safety and effectiveness concerns. Dr. John Krystal, a Yale School of Medicine psychiatrist who has followed the field closely, emphasizes that psychedelics should be approached as "a serious medical procedure that carries risks that must be carefully managed."
As the psychedelic retreat industry continues its rapid expansion, the tension between commercial growth and participant safety remains unresolved, with experts calling for clearer standards and regulatory frameworks to protect vulnerable individuals seeking healing through these unconventional experiences.
